P2Y inhibition by clopidogrel increases adverse clinical events after transcatheter aortic valve replacement.
Fiche publication
Date publication
mai 2022
Journal
International journal of cardiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr OHANA Mickaël
Tous les auteurs :
Matsushita K, Marchandot B, Kibler M, Heger J, Peillex M, Trimaille A, Hess S, Grunebaum L, Ohana M, Reydel A, Jesel L, Ohlmann P, Morel O
Lien Pubmed
Résumé
Dual antiplatelet therapy (DAPT) has been proposed to explain the increased occurrence of bleeding events after transcatheter aortic valve replacement (TAVR) despite no relevant study exploring the extent of platelet inhibition. In the present study, we sought to assess whether P2Y inhibition by clopidogrel impacts clinical outcomes in TAVR patients.
Mots clés
Antiplatelet therapy, Bleeding, Transcatheter aortic valve replacement
Référence
Int J Cardiol. 2022 May 4;: